Results 141 to 150 of about 785,637 (307)
Survival rate of patients with esophageal squamous cell carcinoma
مجله دانشگاه علوم پزشکی گرگان, 2017 Background and Objective: Squamous carcinoma accounts for the majority of esophageal carcinoma worldwide. This study was done to evaluate the survival rate of patients with esophageal cancer in Iran.
A Basi +4 more
doaj
Proliferative and survival pathways in oesophageal cancer [PDF]
, 2011 Includes abstract.Includes bibliographical references.Oesophageal squamous cell carcinoma (OSCC) is the 8th most common cancer worldwide with high incidence in areas that include China, Iran and South Africa. The current treatment available for OSCC does
Esau, Luke Emmanuel
core
New‐Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank
International Journal of Cancer, EarlyView.ABSTRACT The prevalence of type 2 diabetes mellitus (T2DM) is rising rapidly in China and is linked to increased cancer risk, but causality remains unclear due to biases. We examined the causal effect of T2DM on cancer risk using bias‐minimizing methods.
Mengying Wang +9 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt +7 more
wiley +1 more source
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
Radiotherapy for esophageal carcinoma: dose, response and survival
, 2017 Yijun Luo,1,* Qingfeng Mao,2,3,* Xiaoli Wang,1 Jinming Yu,3 Minghuan Li3 1Department of Oncology, The People’s Hospital of Jiangxi, Nanchang, 2School of Medical and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences ...
Mao Q, Luo Y, Wang X, Yu J, Li M
core
International Journal of Cancer, EarlyView.ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor +8 more
wiley +1 more source
iMetaMed, EarlyView.A pan‐cancer atlas deciphers tumor‐induced reprogramming in bone metastases. Malignant evolution toward MYC/proliferation is a hallmark of bone metastases. Niche‐mediated immune dysfunction is characterized by immature pDCs, impaired antigen presentation and phagocytosis in TAMs, and exhausted T cells.
Yitong Pan +4 more
wiley +1 more source
iMeta, EarlyView.The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
The role of deubiquitinating enzymes and their inhibitors in esophageal carcinoma (Review). [PDF]
Int J OncolZhao Y, He C, Chen K, Sun N, He R, Li G.
europepmc +1 more source